Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 6 | 2025 | 243 | 0.810 |
Why?
|
| Protoporphyria, Erythropoietic | 1 | 2018 | 2 | 0.560 |
Why?
|
| Cholestasis | 1 | 2018 | 170 | 0.470 |
Why?
|
| Hypertension, Portal | 2 | 2020 | 78 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2025 | 39 | 0.260 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2007 | 6 | 0.260 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2007 | 10 | 0.260 |
Why?
|
| Carcinoma | 2 | 2021 | 283 | 0.240 |
Why?
|
| Iodine Radioisotopes | 1 | 2025 | 65 | 0.230 |
Why?
|
| Conjunctiva | 1 | 2007 | 196 | 0.220 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2022 | 400 | 0.210 |
Why?
|
| Eosinophilic Esophagitis | 2 | 2016 | 78 | 0.210 |
Why?
|
| Pyridines | 1 | 2025 | 258 | 0.210 |
Why?
|
| Nocardia Infections | 1 | 2024 | 13 | 0.210 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2024 | 50 | 0.200 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2021 | 63 | 0.190 |
Why?
|
| Pyrazoles | 1 | 2025 | 355 | 0.190 |
Why?
|
| Loss of Function Mutation | 1 | 2024 | 170 | 0.190 |
Why?
|
| Insulins | 1 | 2022 | 17 | 0.180 |
Why?
|
| Homozygote | 1 | 2024 | 535 | 0.180 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1589 | 0.180 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2021 | 8 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 747 | 0.170 |
Why?
|
| Child | 17 | 2024 | 26214 | 0.170 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1216 | 0.170 |
Why?
|
| Thyroid Gland | 1 | 2021 | 98 | 0.160 |
Why?
|
| Granuloma, Pyogenic | 1 | 2020 | 6 | 0.160 |
Why?
|
| Rhabdomyosarcoma | 1 | 2024 | 229 | 0.160 |
Why?
|
| Cough | 2 | 2020 | 98 | 0.160 |
Why?
|
| Carcinoma, Papillary | 1 | 2020 | 91 | 0.160 |
Why?
|
| Adolescent | 16 | 2025 | 20815 | 0.150 |
Why?
|
| DNA, Neoplasm | 1 | 2020 | 282 | 0.150 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 1547 | 0.150 |
Why?
|
| Mutation, Missense | 1 | 2024 | 923 | 0.150 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 903 | 0.150 |
Why?
|
| Orchiectomy | 1 | 2019 | 46 | 0.150 |
Why?
|
| Liver Diseases | 2 | 2024 | 378 | 0.140 |
Why?
|
| Trachea | 1 | 2020 | 207 | 0.140 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2018 | 4 | 0.140 |
Why?
|
| Radiotherapy | 1 | 2019 | 120 | 0.140 |
Why?
|
| Developmental Disabilities | 1 | 2024 | 782 | 0.140 |
Why?
|
| Osteosarcoma | 2 | 2018 | 275 | 0.140 |
Why?
|
| Provitamins | 1 | 2018 | 3 | 0.140 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 92 | 0.140 |
Why?
|
| Cholestyramine Resin | 1 | 2018 | 13 | 0.140 |
Why?
|
| Photosensitivity Disorders | 1 | 2018 | 10 | 0.140 |
Why?
|
| Phenylurea Compounds | 1 | 2018 | 57 | 0.140 |
Why?
|
| Portal Vein | 1 | 2018 | 84 | 0.140 |
Why?
|
| Cholagogues and Choleretics | 1 | 2018 | 24 | 0.140 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2018 | 38 | 0.140 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 112 | 0.140 |
Why?
|
| Pruritus | 1 | 2018 | 50 | 0.140 |
Why?
|
| Laser Therapy | 1 | 2020 | 241 | 0.140 |
Why?
|
| beta Carotene | 1 | 2018 | 35 | 0.130 |
Why?
|
| Quinolines | 1 | 2018 | 115 | 0.130 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 410 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 142 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2022 | 685 | 0.130 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 225 | 0.130 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 33 | 0.130 |
Why?
|
| Image-Guided Biopsy | 1 | 2017 | 38 | 0.130 |
Why?
|
| Biliary Atresia | 1 | 2020 | 223 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 126 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2018 | 124 | 0.120 |
Why?
|
| Polyps | 1 | 2017 | 38 | 0.120 |
Why?
|
| Wolman Disease | 1 | 2016 | 7 | 0.120 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2017 | 101 | 0.120 |
Why?
|
| Esophageal Mucosa | 1 | 2016 | 12 | 0.120 |
Why?
|
| Male | 18 | 2024 | 64575 | 0.120 |
Why?
|
| Galectin 3 | 1 | 2016 | 32 | 0.120 |
Why?
|
| Cystic Fibrosis | 1 | 2018 | 266 | 0.120 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 1 | 2015 | 9 | 0.120 |
Why?
|
| Itraconazole | 1 | 2015 | 24 | 0.120 |
Why?
|
| Humans | 26 | 2025 | 130600 | 0.120 |
Why?
|
| Budesonide | 1 | 2015 | 18 | 0.120 |
Why?
|
| Histoplasma | 1 | 2015 | 37 | 0.110 |
Why?
|
| Cushing Syndrome | 1 | 2015 | 22 | 0.110 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2015 | 19 | 0.110 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2015 | 16 | 0.110 |
Why?
|
| Thyroid Nodule | 1 | 2015 | 21 | 0.110 |
Why?
|
| Bronchiectasis | 1 | 2015 | 22 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1875 | 0.110 |
Why?
|
| Gene Fusion | 1 | 2015 | 57 | 0.110 |
Why?
|
| Histoplasmosis | 1 | 2015 | 55 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 976 | 0.110 |
Why?
|
| Eosinophilia | 1 | 2016 | 110 | 0.110 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2015 | 108 | 0.110 |
Why?
|
| Stomach | 1 | 2017 | 270 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 5166 | 0.110 |
Why?
|
| Mutation | 2 | 2020 | 6092 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 165 | 0.100 |
Why?
|
| Pollen | 1 | 2014 | 38 | 0.100 |
Why?
|
| Liver Transplantation | 2 | 2020 | 1131 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 360 | 0.100 |
Why?
|
| Fungi | 1 | 2014 | 72 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 568 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 470 | 0.100 |
Why?
|
| Anus Diseases | 1 | 2013 | 15 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2018 | 1242 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 1367 | 0.100 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 324 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2021 | 237 | 0.090 |
Why?
|
| Child, Preschool | 8 | 2020 | 15014 | 0.090 |
Why?
|
| Allergens | 1 | 2014 | 344 | 0.090 |
Why?
|
| Pediatric Obesity | 1 | 2016 | 413 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 569 | 0.080 |
Why?
|
| Crohn Disease | 1 | 2013 | 290 | 0.080 |
Why?
|
| Female | 14 | 2024 | 70465 | 0.070 |
Why?
|
| Infant | 6 | 2024 | 13288 | 0.070 |
Why?
|
| Thyroidectomy | 2 | 2021 | 97 | 0.070 |
Why?
|
| Young Adult | 6 | 2020 | 10021 | 0.070 |
Why?
|
| Liver | 1 | 2016 | 1787 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1805 | 0.070 |
Why?
|
| Biopsy | 3 | 2017 | 1244 | 0.070 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 35 | 0.060 |
Why?
|
| Lymphatic Metastasis | 2 | 2020 | 425 | 0.060 |
Why?
|
| Vimentin | 1 | 2007 | 59 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 1277 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2020 | 12881 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2007 | 411 | 0.050 |
Why?
|
| R-SNARE Proteins | 1 | 2024 | 21 | 0.050 |
Why?
|
| Prognosis | 3 | 2020 | 4869 | 0.050 |
Why?
|
| Pneumonia | 2 | 2020 | 340 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1597 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2021 | 17569 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 526 | 0.050 |
Why?
|
| Vesicular Transport Proteins | 1 | 2024 | 138 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2007 | 722 | 0.050 |
Why?
|
| Antibodies, Antinuclear | 1 | 2022 | 31 | 0.050 |
Why?
|
| Neoplasms | 1 | 2017 | 2985 | 0.040 |
Why?
|
| Salivary Glands | 1 | 2021 | 35 | 0.040 |
Why?
|
| Phenotype | 2 | 2024 | 4484 | 0.040 |
Why?
|
| Adult | 4 | 2024 | 31169 | 0.040 |
Why?
|
| Vomiting | 1 | 2020 | 103 | 0.040 |
Why?
|
| Portoenterostomy, Hepatic | 1 | 2020 | 62 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2024 | 657 | 0.040 |
Why?
|
| Drosophila | 1 | 2024 | 769 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 3409 | 0.040 |
Why?
|
| Alleles | 1 | 2024 | 1675 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2018 | 189 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2024 | 769 | 0.030 |
Why?
|
| DiGeorge Syndrome | 1 | 2018 | 83 | 0.030 |
Why?
|
| Chondrosarcoma | 1 | 2017 | 14 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2021 | 559 | 0.030 |
Why?
|
| Rhabdoid Tumor | 1 | 2017 | 46 | 0.030 |
Why?
|
| Nitrosation | 1 | 2016 | 4 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 1479 | 0.030 |
Why?
|
| Galectins | 1 | 2016 | 24 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2021 | 800 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2016 | 65 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 714 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2017 | 121 | 0.030 |
Why?
|
| Chimerism | 1 | 2015 | 29 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 1000 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2016 | 143 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8556 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2015 | 119 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2015 | 238 | 0.030 |
Why?
|
| Telomerase | 1 | 2015 | 153 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2017 | 304 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 1157 | 0.030 |
Why?
|
| beta Catenin | 1 | 2015 | 198 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2016 | 287 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2015 | 217 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 777 | 0.020 |
Why?
|
| Papilloma | 1 | 2013 | 22 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 630 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2016 | 465 | 0.020 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 276 | 0.020 |
Why?
|
| Infliximab | 1 | 2013 | 61 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 1207 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 2901 | 0.020 |
Why?
|
| Weight Gain | 1 | 2015 | 383 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2063 | 0.020 |
Why?
|
| Urban Population | 1 | 1994 | 282 | 0.020 |
Why?
|
| Population Surveillance | 1 | 1994 | 394 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 1211 | 0.020 |
Why?
|
| Proteomics | 1 | 2016 | 616 | 0.020 |
Why?
|
| Pedigree | 1 | 2015 | 1674 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 900 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 892 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 2298 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2021 | 3117 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 2601 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 2830 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 981 | 0.020 |
Why?
|
| Pediatrics | 1 | 2017 | 1242 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 3385 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 1994 | 4043 | 0.010 |
Why?
|
| Animals | 1 | 2024 | 33835 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 10976 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 1994 | 28 | 0.010 |
Why?
|
| Peru | 1 | 1994 | 54 | 0.010 |
Why?
|
| Bias | 1 | 1994 | 148 | 0.010 |
Why?
|
| Dyspnea | 1 | 1994 | 159 | 0.010 |
Why?
|
| Fever | 1 | 1994 | 313 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1994 | 2086 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 1994 | 3353 | 0.000 |
Why?
|